Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner
Journal of Endocrinology · 11.06.2024 · 262 (2)
DOI: 10.1530/joe-24-0032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinology, erschienen am 11.06.2024. Verfasst von Jordan S F Chan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Liraglutide, Diabetic Cardiomyopathies, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: CIHR.
Abstract (Originalsprache)
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used for the treatment of T2D, has been shown to alleviate diabetic cardiomyopathy (DbCM) in experimental T2D, which was associated with increased myocardial glucose oxidation. To determine whether this increase in glucose oxidation is necessary for cardioprotection, we hypothesized that liraglutide’s ability to alleviate DbCM would be abolished in mice with cardiomyocyte-specific deletion of pyruvate dehydrogenase (PDH; Pdha1 CM−/− mice), the rate-limiting enzyme of glucose oxidation. Male Pdha1 CM−/− mice and their α-myosin heavy chain Cre expressing littermates (αMHC Cre mice) were subjected to experimental T2D via 10 weeks of high-fat diet supplementation, with a single low-dose injection of streptozotocin (75 mg/kg) provided at week 4. All mice were randomized to treatment with either vehicle control or liraglutide (30 µg/kg) twice daily during the final 2.5 weeks, with cardiac function assessed via ultrasound echocardiography. As expected, liraglutide treatment improved glucose homeostasis in both αMHC Cre and Pdha1 CM−/− mice with T2D, in the presence of mild weight loss. Parameters of systolic function were unaffected by liraglutide treatment in both αMHC Cre and Pdha1 CM−/− mice with T2D. However, liraglutide treatment alleviated diastolic dysfunction in αMHC Cre mice, as indicated by an increase and decrease in the e′/a′ and E/e′ ratios, respectively. Conversely, liraglutide failed to rescue these indices of diastolic dysfunction in Pdha1 CM−/− mice. Our findings suggest that increases in glucose oxidation are necessary for GLP-1R agonist mediated alleviation of DbCM. As such, strategies aimed at increasing PDH activity may represent a novel approach for the treatment of DbCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
- Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
- Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada.
ORCID-Profile: Kunyan Yang, John R Ussher
Förderung
- CIHR
Zitieren
APA
Chan, J. S. F., Greenwell, A. A., Saed, C. T., Stenlund, M. J., Mangra-Bala, I. A., Tabatabaei Dakhili, S. A., Yang, K., Ferrari, S. R., Eaton, F., Gopal, K., & Ussher, J. R. (2024). Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner. Journal of Endocrinology, 262(2). https://doi.org/10.1530/joe-24-0032
Vancouver
Chan JSF, Greenwell AA, Saed CT, Stenlund MJ, Mangra-Bala IA, Tabatabaei Dakhili SA, et al. Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner. Journal of Endocrinology. 2024;262(2). doi:10.1530/joe-24-0032
BibTeX
@article{Chan2024,
author = {Chan, Jordan S F and Greenwell, Amanda A and Saed, Christina T and Stenlund, Magnus J and Mangra-Bala, Indiresh A and Tabatabaei Dakhili, Seyed Amirhossein and Yang, Kunyan and Ferrari, Sally R and Eaton, Farah and Gopal, Keshav and Ussher, John R},
title = {Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner},
journal = {Journal of Endocrinology},
year = {2024},
volume = {262},
number = {2},
doi = {10.1530/joe-24-0032}
}
EUVIMED